Page 149 - CW E-Magazine (11-3-2025)

Pharmaceuticals Pharmaceuticals

DIVERSIFICATION BCG-IPSO REPORT
Granules acquires peptides fi rm; forays into CDMO CRDMO sector growth potential pegged at up to

space $22-bn by 2035

Hyderabad-based Granules India The acquisition aligns with The Indian Contract Research,
has inked a pact to acquire Senn Chemi- Granules’ vision to enter the rapidly Development, and Manufacturing
cals AG, a Swiss-based Contract Deve- expanding peptide-based anti-diabetic Organisation (CRDMO) sector is at an
lopment and Manufacturing Organisa- and anti-obesity market, including infl ection point, with the potential to
tion (CDMO) specialising in peptides GLP-1 receptor agonists and other grow to between $22-bn and $25-bn
for Rs. 192-crore. next-generation therapeutics. by 2035, as per a new report, Unleashing
our vision to transform Granules into a the Tiger: Indian CRDMO Sector
“By entering the rapidly growing science and innovation-led organisa- Granules and Senn have been deve- 2025’, published by Boston Consul-
peptide therapeutics segment and tion and become a trusted partner in loping two GLP-1 based APIs, and ting Group (BCG) and Innova-
acquiring CDMO capabilities, we are complex and specialised therapeutics,” both projects are progressing well, and tive Pharmaceutical Services Organi-
expanding into next-generation ther- he added. more peptide-based APIs are planned sation (IPSO).
apeutics that align with our commit- to be added in the portfolio, to be
ment to innovation and affordability,” The acquisition, which is expected developed using Senn’s R&D capa- The report highlights India’s strong
said Mr. Krishna Prasad Chigurupati, to close in the fi rst half of 2025, brings bilities. foundation in small molecule capabili-
Chairman & Managing Director, Granules Senn’s expertise in Liquid-Phase Pep- ties, sustainable cost advantages and  The push to de-risk supply chains In a step toward advancing India’s
India. tide Synthesis (LPPS) and Solid-Phase “With Granules’ scale, operational emerging biologics expertise, posi- is making India a preferred out- CRDMO sector, eleven of the coun-
Peptide Synthesis (SPPS) to Granules effi ciency, and global reach in pharma- tioning the country as a global leader
“Senn’s expertise in peptide syn- along with a strong CDMO business ceuticals industry, we see strategic fi t in pharmaceutical innovation. sourcing destination; try’s leading CRDMO companies have
thesis, coupled with our large-scale, and established customer relationship, and tremendous potential to accelerate  Pricing pressures and policies like come together to launch IPSO. This
the Infl ation Reduction Act (IRA) collective initiative aims to advance
cost-effi cient manufacturing capabili- including innovators and brand owners our growth and expand our capabilities Key fi ndings are accelerating offshoring; India’s CRDMO sector and is dedicated
ties, positions us to deliver high-qua- across pharma, cosmetics, amino acid in rapidly growing peptide therapeu- India’s CRDMO market is growing  Rising demand for advanced moda- to fostering pharmaceutical and health-
lity peptide-based solutions globally. derivatives (AAD) & theragnostic seg- tics,” Mr. Rico Wiedenbruch, Chairman, at a 15% CAGR, outpacing global lities like ADCs, gene therapy, and care innovation in India, that supports
This acquisition is a pivotal moment in ments, the company said. Senn Chemicals said. industry growth, fuelled by its cost
advantage over the West and 90% faster RNA therapeutics is boosting spe- research, policy advocacy and industry
collaboration to drive the next wave of
cialised CRDMO services; and
Cadila Pharma readies new warehouse in Ahmedabad project startup times. Global supply  Growing investments in R&D and biotech and pharma growth.
chain realignments are unlocking a
$10-bn opportunity for Indian CRDMOs, infrastructure are strengthening
Ahmedabad-based Cadila Pharma- environments and with Western pharma companies India’s innovation ecosystem. Commenting on the sector’s poten-
ceuticals has announced the expan- cutting-edge inven- looking for alternative hubs. New moda- tial, Mr. Vikash Agarwalla, Manag-
sion of its warehouse at its Dholka tory management lities such as Antibody Drug Con- Five key imperatives: ing Director and Partner at BCG, said,
(Ahmedabad). systems further sup- jugates (ADCs), DNA & RNA thera-  To unlock India’s CRDMO poten- “India’s CRDMO industry is at the
port business growth peutics are witnessing a 25-35% tial, the report highlights fi ve key beginning of its “Amritkaal”, with many
Spanning approximately 30,000 sq. ft., by enhancing supply annual growth, providing India with an imperatives: strong tailwinds. Our report highlights
the new warehouse is designed chain reliability,” a opportunity to leapfrog in innovation.  Accelerating talent development how India’s inherent strengths – small
to optimise storage and distribution. company press note Indian biotech and pharma innova- through industry-ready curricula molecule expertise, cost competitive-
With a storage capacity of 3,888 informed. tion is accelerating, backed by over and upskilling initiatives; ness, and a rapidly growing innovation
pallets in the main warehouse and 75 Rs. 25,000-crore in government funding  Streamlining policies with a CRDMO- ecosystem – provides the springboard
pallets in a temperature-controlled “By integrat- to foster a self-suffi cient, local innova- focused regulatory framework; to becoming a dominant player in the
cold room, it ensures safe storage for ing automation and tion-driven ecosystem.  Strengthening the supplier ecosystem global CRDMO market. However,
sensitive products such as vaccines advanced logistics by incentivising local manufacturers unlocking this full potential will require
and insulin, the company said. The “This expansion reinforces Cadila solutions, we are not only improv- Four key tailwinds: and establishing Innovation Parks; collective push from both industry and
facility is equipped with advanced Pharmaceuticals’ mission to provide ing effi ciency but also reinforcing our  While India holds a 2-3% share  Expanding capital access by desig- policymakers. With the right invest-
Warehouse Management Systems seamless supply chain management, ability to meet the evolving needs of the of the $140-bn to $145-bn global nating CRDMO as a sunrise sector; and ments in infrastructure, talent, and policy
(WMS), a fi xed racking system, Very ensuring timely and effi cient distribu- pharmaceutical industry,” said Dr. Rajiv CRDMO market, it has the potential  Enhancing sustainability through simplifi cations, we can truly emerge as
Narrow Aisle (VNA) equipment, and tion of critical healthcare products. The Modi, the company’s Chairman & to become a global leader with four green practices and adherence to the innovation and manufacturing hub
reach trucks. warehouse’s temperature-controlled Managing Director. key tailwinds driving this growth: global ESG benchmarks. for the global pharma industry.”

148 Chemical Weekly March 11, 2025 Chemical Weekly March 11, 2025 149

Contents Index to Advertisers Index to Products Advertised